TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Instagram Outage Disrupts Thousands of U.S. Users 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Celltrion Pharmaceutical company has finally completed merging with its Celltrion Healthcare affiliate. This comes after the board of directors has given the “go-ahead” signal for the merger on Thursday, Dec. 28.
The unification of Celltrion and Celltrion Healthcare happened three years after the plan was first announced by the former. According to Korea Joongang Daily, the newly formed entity, following the completion of the affiliation, will then proceed to go into another merger process, this time with Celltrion Pharm. This second deal is expected to be completed sometime next year.
New Unified Entity to Enter Another Merger Deal
The new company was formed after Celltrion and Celltrion Healthcare were successfully consolidated into one entity. This will be merged with Celltrion Pharma, and the resulting new organization will have Celltrion Holdings as its largest shareholder with a 21.5% share.
In any case, it was mentioned that Celltrion’s founder and chairman, Seo Jung Jin, still has a 98.1% stake in the group’s holdings firm. As three firms are being consolidated with this succession of mergers, the company is aiming to reach KRW2 trillion won or about $9 billion in annual revenue by the year 2030.
“Celltrion was able to secure massive funds through the merger and will invest them in our new future growth engines like biosimilars, new drug development and mergers and acquisitions,” Celltrion commented.
Appointment of Three CEOs for the Merged Company
The integrated Celltrion company is set to be managed by three chief executive officers. Korea’s Alphabiz reported that the appointed executives include Ki Woo Sung, who will supervise the manufacturing and development division; Kim Hyung Ki, who will be assigned to manage the global sales unit; and Seo Jin Seok, who will become head of the business management unit.
Celltrion will start operating as a representative system for the three chiefs soon.
Photo by: Celltrion Media Center
